Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 32 articles:
HTML format

Single Articles

    July 2021
  1. SMERAT T, Khdour M, Abdoh Q, Hallak H, et al
    Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.
    Lancet. 2021;398 Suppl 1:S48.
    PubMed     Abstract available

    June 2021
  2. HOLMER AK, Singh S
    Expanding targeted immune modulators in ulcerative colitis.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00891.

  3. FEAGAN BG, Danese S, Loftus EV Jr, Vermeire S, et al
    Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00666.
    PubMed     Abstract available

    March 2020
  4. KOSKENVUO L, Sallinen V
    Is preoperative bowel preparation always superfluous? - Authors' reply.
    Lancet. 2020;395:782.

    January 2020
  5. DAMAS OM, Abreu MT
    Are patients with ulcerative colitis still at increased risk of colon cancer?
    Lancet. 2020;395:92-94.

  6. OLEN O, Erichsen R, Sachs MC, Pedersen L, et al
    Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.
    Lancet. 2020;395:123-131.
    PubMed     Abstract available

    April 2019
  7. HYAMS JS, Davis Thomas S, Gotman N, Haberman Y, et al
    Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
    Lancet. 2019;393:1708-1720.
    PubMed     Abstract available

    March 2019
  8. ASHTON JJ, Beattie RM
    Personalised therapy for inflammatory bowel disease.
    Lancet. 2019 Mar 29. pii: S0140-6736(18)33125.

  9. GECSE KB, D'Haens GR
    Infliximab biosimilar CT-P13 in Crohn's disease.
    Lancet. 2019 Mar 28. pii: S0140-6736(18)32778.

  10. YE BD, Pesegova M, Alexeeva O, Osipenko M, et al
    Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Lancet. 2019 Mar 28. pii: S0140-6736(18)32196.
    PubMed     Abstract available

    December 2018
    Targeting Crohn's disease.
    Lancet. 2018;390:2742-2744.

  12. COLOMBEL JF, Panaccione R, Bossuyt P, Lukas M, et al
    Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Lancet. 2018;390:2779-2789.
    PubMed     Abstract available

    April 2018
  13. COLOMBEL JF, Panaccione R, Petersson J, Robinson AM, et al
    Clinical disease activity in the CALM study - Authors' reply.
    Lancet. 2018;391:1482.

  14. HERFARTH H, Long MD, Isaacs KL
    Clinical disease activity in the CALM study.
    Lancet. 2018;391:1481-1482.

    October 2017
  15. KAMM MA
    Rapid changes in epidemiology of inflammatory bowel disease.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32669.

  16. NG SC, Shi HY, Hamidi N, Underwood FE, et al
    Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32448.
    PubMed     Abstract available

  17. NORMAN SD, Murray IA, Shetty D, Bendall RP, et al
    Jaundice, abdominal pain, and fever in a young woman.
    Lancet. 2017;390:1713-1714.

    September 2017
  18. KUGATHASAN S, Denson LA, Hyams JS
    Exclusive and partial enteral nutrition for Crohn's disease - Authors' reply.
    Lancet. 2017;390:1486-1487.

    Exclusive and partial enteral nutrition for Crohn's disease.
    Lancet. 2017;390:1486.

    July 2017
  20. DE JONG MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, et al
    Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.
    Lancet. 2017 Jul 14. pii: S0140-6736(17)31327.
    PubMed     Abstract available

    June 2017
  21. VESELY R, Richardson P
    The switch to infliximab biosimilars.
    Lancet. 2017;389:2266-2268.

    May 2017
    Towards therapeutic choices in ulcerative colitis.
    Lancet. 2017 May 17. pii: S0140-6736(17)31263.

  23. VERMEIRE S, Sandborn WJ, Danese S, Hebuterne X, et al
    Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 May 17. pii: S0140-6736(17)30930.
    PubMed     Abstract available

  24. JORGENSEN KK, Olsen IC, Goll GL, Lorentzen M, et al
    Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Lancet. 2017 May 11. pii: S0140-6736(17)30068.
    PubMed     Abstract available

    February 2017
  25. PARAMSOTHY S, Kamm MA, Kaakoush NO, Walsh AJ, et al
    Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Lancet. 2017 Feb 14. pii: S0140-6736(17)30182.
    PubMed     Abstract available

    Is intensity the solution for FMT in ulcerative colitis?
    Lancet. 2017 Feb 14. pii: S0140-6736(17)30313.

    January 2017
    A cure for Crohn's disease by 2032.
    Lancet. 2017;389:226.

    Filgotinib for Crohn's disease-expanding treatment options.
    Lancet. 2017;389:228-229.

  29. VERMEIRE S, Schreiber S, Petryka R, Kuehbacher T, et al
    Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Lancet. 2017;389:266-275.
    PubMed     Abstract available

    November 2016
  30. UNGARO R, Mehandru S, Allen PB, Peyrin-Biroulet L, et al
    Ulcerative colitis.
    Lancet. 2016 Nov 30. pii: S0140-6736(16)32126.
    PubMed     Abstract available

    September 2016
  31. CICCOCIOPPO R, Corazza GR
    Mesenchymal stem cells for fistulising Crohn's disease.
    Lancet. 2016;388:1251-2.

  32. PANES J, Garcia-Olmo D, Van Assche G, Colombel JF, et al
    Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
    Lancet. 2016;388:1281-90.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.